IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells
Authors
Keywords
Ovarian cancer, IL-6/STAT3/HIF-1α, Nuclear translocation, Chemoresistance
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 894, Issue -, Pages 173817
Publisher
Elsevier BV
Online
2020-12-18
DOI
10.1016/j.ejphar.2020.173817
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
- (2020) Shannon Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Suppression of ovarian cancer by low-intensity ultrasound through depletion of IL-6/STAT3 inflammatory pathway-maintained cancer stemness
- (2020) Ting Gong et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer
- (2019) In-Hye Ham et al. Molecular Cancer
- Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells
- (2019) Carolina Méndez-Blanco et al. Cancers
- Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1α
- (2018) Ke Wang et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension
- (2018) Soni Savai Pullamsetti et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer
- (2018) Hassan Yousefi et al. TUMORI
- IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer
- (2018) Hassan Yousefi et al. TUMORI JOURNAL
- A feed-forward loop between nuclear translocation of CXCR4 and HIF-1α promotes renal cell carcinoma metastasis
- (2018) Yi Bao et al. ONCOGENE
- Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
- (2017) Marcela Moisés Maluf Sanguinete et al. IMMUNOLOGICAL INVESTIGATIONS
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression
- (2017) Jie Qin et al. Scientific Reports
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of interleukin-6 in cancer progression and therapeutic resistance
- (2016) Neeraj Kumari et al. TUMOR BIOLOGY
- Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro
- (2016) Soochi Kim et al. Oncotarget
- Classic IL-6R signalling is dispensable for intestinal epithelial proliferation and repair
- (2016) K Aden et al. Oncogenesis
- Ovarian cancer: beyond resistance
- (2015) David Holmes NATURE
- Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells
- (2015) NA-HYUN KIM et al. Oncology Letters
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- HIF-1 Signaling in Drug Resistance to Chemotherapy
- (2014) N.A. Warfel et al. CURRENT MEDICINAL CHEMISTRY
- Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis
- (2014) Yue Jin et al. TUMOR BIOLOGY
- Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer
- (2014) MCA Wouters et al. OncoImmunology
- Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
- (2012) Eveline M. Dijkgraaf et al. CURRENT PHARMACEUTICAL DESIGN
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
- (2011) M. S. Anglesio et al. CLINICAL CANCER RESEARCH
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
- (2010) Yue Wang et al. CANCER LETTERS
- Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer
- (2009) Bharat B. Aggarwal et al. Annals of the New York Academy of Sciences
- Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
- (2009) Karin de Visser et al. CURRENT PHARMACEUTICAL DESIGN
- Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3
- (2009) Karuppaiyah Selvendiran et al. INTERNATIONAL JOURNAL OF CANCER
- Quantitative Phosphoproteomic Analysis of the STAT3/IL-6/HIF1α Signaling Network: An Initial Study in GSC11 Glioblastoma Stem Cells
- (2009) Carol L. Nilsson et al. JOURNAL OF PROTEOME RESEARCH
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
- (2009) G L Semenza ONCOGENE
- Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma
- (2009) James A. Bonner et al. RADIOTHERAPY AND ONCOLOGY
- Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study
- (2008) Alexandros Daponte et al. BMC CANCER
- Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1 RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells
- (2008) G. Niu et al. MOLECULAR CANCER RESEARCH
- Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
- (2008) Nadine N. Bewry et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started